Molecular staging individualizing cancer management.

Authors

• Alex Mejia
• Stephanie Schulz
• Terry Hyslop
• David S Weinberg
• Scott A Waldman

Publication/Presentation Date

4-1-2012

Abstract

Although the most important prognostic and predictive marker in colorectal cancer is tumor cells in lymph nodes, approximately 30% of patients who are node-negative die from occult metastases. Molecular staging employing specific markers and sensitive detection technologies has emerged as a powerful platform to assess prognosis in node-negative colon cancer. Integrating molecular staging into algorithms that individualize patient management will require validation and the definition of relationships between occult tumor cells, prognosis, and responses to chemotherapy.

Volume

105

Issue

5

First Page

468

Last Page

474

ISSN

1096-9098

Published In/Presented At

Mejia, A., Schulz, S., Hyslop, T., Weinberg, D. S., & Waldman, S. A. (2012). Molecular staging individualizing cancer management. Journal of surgical oncology, 105(5), 468–474. https://doi.org/10.1002/jso.21858

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

PubMedID

22441898

Department(s)

Administration and Leadership

Document Type

Article